Back to search resultsSummaryRMgm-4710
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 31797966 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Angrisano F, Blagborough AM |
Name Group/Department | Department of Life Sciences |
Name Institute | Imperial College of Science, Technology and Medicine |
City | London |
Country | UK |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4710 |
Principal name | ΔPDI-Trans |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Normal production of gametocytes; normal activation, gamete formation and egress of gametocytes/gametes from host red blood cells. No ookinete formation in vitro. Crossing experiments with mutants defective in either male or female gamete production showed that ΔPDI-Trans female gametes are fertile while ΔPDI-Trans male gamete fertility is strongly reduced. |
Oocyst | Normal production of gametocytes; normal activation, gamete formation and egress of gametocytes/gametes from host red blood cells. No ookinete formation in vitro. Crossing experiments with mutants defective in either male or female gamete production showed that ΔPDI-Trans female gametes are fertile while ΔPDI-Trans male gamete fertility is strongly reduced. Strongly reduced oocyst formation (63-96% inhibition) of oocyst formation |
Sporozoite | Strongly reduced oocyst formation (63-96% inhibition) of oocyst formation; the small number of oocysts formed are morphologically normal and form normal sporozoites that are infective to mice. |
Liver stage | Strongly reduced oocyst formation (63-96% inhibition) of oocyst formation; the small number of oocysts formed are morphologically normal and form normal sporozoites that are infective to mice. |
Additional remarks phenotype | Mutant/mutation Evidence is presented that: - PDI shows classical PDI activity |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0820300 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0919400 | ||||||||||||||||||||||||
Gene product | protein disulfide isomerase | ||||||||||||||||||||||||
Gene product: Alternative name | PDI9; PDI-Trans | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | Yes | ||||||||||||||||||||||||
Name of PlasmoGEM construct/vector | PbGEM-239637 | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |